Regenosca develops TissueSpan bio-implants—temporary scaffolds that guide the body’s own cells to regenerate urethral tissue without harvesting patient tissue. The implants are intended for endoscopic delivery to treat urethral strictures, a condition affecting nearly a million patients in the U.S. annually. Current endoscopic methods can have failure rates up to 80%, and Regenosca’s approach aims to reduce invasiveness, pain, and recovery time. The company reported first‑in‑man study results showing perfect tissue regrowth at the implantation site. Leadership includes CEO Eva‑Maria Balet and CTO Mattias Larsson, and the company recently added Aydin Kurt‑Elli to its board. Regenosca has received awards at the European Association of Urology and the American Urological Association and cites a global market opportunity of up to USD 5 billion annually for urethral stricture treatments.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2024